Hagop M. Kantarjian
University of Texas MD Anderson Cancer Center
4152 Papers
32.7K Citations
Hagop M. Kantarjian is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 204, co-authored 3708 publications. Previous affiliations of Hagop M. Kantarjian include Rice University & University of Chicago.
Chat about Author
Papers
Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.
Richard T. Silver,Moshe Talpaz,Charles L. Sawyers,Brian J. Druker,Andreas Hochhaus,Charles A. Schiffer,François Guilhot,John M. Goldman,B. Douglas Smith,Manisha Mone,Tillmann Kranhnke,Hagop M. Kantarjian +11 more
TL;DR: In large phase II studies, continuous imatinib treatment is safe and has improved progression-free survival of patients at all stages of CML.
87
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Yasuhiro Oki,Hagop M. Kantarjian,Xian Zhou,Jorge E. Cortes,Stefan Faderl,Srdan Verstovsek,Susan O'Brien,Charles Koller,Miloslav Beran,B. Nebiyou Bekele,Sherry Pierce,Deborah A. Thomas,Farhad Ravandi,William G. Wierda,Francis J. Giles,Alessandra Ferrajoli,Elias Jabbour,Michael J. Keating,Carlos E. Bueso-Ramos,Elihu H. Estey,Guillermo Garcia-Manero +20 more
TL;DR: The results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.
87
Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia
Francis J. Giles,David A. Rizzieri,Judith E. Karp,Norbert Vey,Farhad Ravandi,Stefan Faderl,Khuda Dad Khan,Gregor Verhoef,Pierre W. Wijermans,Anjali S. Advani,Gail J. Roboz,Hagop M. Kantarjian,Syed Fazl Ali Bilgrami,Augustin Ferrant,Simon Daenen,Verena Karsten,Ann Cahill,Maher Albitar,Ghulam J. Mufti,Susan O'Brien +19 more
TL;DR: Cloretazine has significant activity and modest extramedullary toxicity in elderly patients with AML or high-risk MDS, and response rates remain consistent despite increasing age and comorbidity.
87
Heterogeneity of non-Hodgkin's lymphoma probed by nucleic acid cytometry
John R. Srigley,Bart Barlogie,James J. Butler,Barbara M. Osborne,Mark Blick,Dennis A. Johnston,Hagop M. Kantarjian,J. M. Reuben,John G. Batsakis,Emil J. Freireich +9 more
TL;DR: Among intermediate-grade and high-grade lymphomas, increased proliferative activity and diploidy were associated with more frequent responses to treatment and allowed an objective approach to lymphoma classification based on ploidy, proliferation, and RNA characteristics that also had prognostic implications.
87
•Journal Article
Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR/ABL-positive Cell Line
Clara Ricci,Barbara Scappini,Vladimir Divoky,Simona Gatto,Francesco Onida,Srdan Verstovsek,Hagop M. Kantarjian,Miloslav Beran +7 more
TL;DR: Preliminary data showing partial reversibility of resistance in these cells suggest that resistance may be multifactorial, and a single-point mutation leading to a substitution of a threonine-to-isoleucine at position 315 of Abl remains unknown.
87